A Promising Finding — With Important Limits Attached
A rigorous clinical trial has produced the first randomized, placebo-controlled human evidence that semaglutide, the active ingredient in Ozempic and Wegovy, may slow biological aging. The finding is generating significant attention among researchers and the public alike. It is also generating premature conclusions that the evidence does not yet support.
